IIVLX | JVMAX | IIVLX / JVMAX | |
Total Expense Ratio | 1.94 | 1.12 | 173% |
Annual Report Gross Expense Ratio | 1.94 | 1.13 | 172% |
Fund Existence | 22 years | 28 years | - |
Gain YTD | -9.018 | -7.710 | 117% |
Front Load | N/A | 5% | - |
Min. Initial Investment | 1000 | 1000 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 591M | 19.6B | 3% |
Annual Yield % from dividends | 0.18 | 0.61 | 29% |
Returns for 1 year | -14.76 | -10.96 | 135% |
Returns for 3 years | -25.41 | -8.30 | 306% |
Returns for 5 years | 16.72 | 46.80 | 36% |
Returns for 10 years | -26.82 | 19.44 | -138% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FTXH | 24.36 | 0.35 | +1.46% |
First Trust Nasdaq Pharmaceuticals ETF | |||
PGZ | 10.13 | 0.12 | +1.20% |
PRINCIPAL REAL ESTATE Income FUND | |||
PFM | 43.48 | 0.24 | +0.56% |
Invesco Dividend Achievers™ ETF | |||
ISTB | 48.22 | N/A | +0.01% |
iShares Core 1-5 Year USD Bond ETF | |||
AMZY | 14.47 | -0.10 | -0.69% |
YieldMax AMZN Option Income Strategy ETF |